Patent and Trademark Office. As of December 12, 1995, MicroCor's application for a patent entitled "Method and Apparatus for Non-Invasively Determining Hematocrit" was allowed by the U.S. Patent and Trademark Office, and such patent issued on June 18, 1996, as Patent No. 5,526,808 with a term of 17 years and an expiration date of June 18, 2013. MicroCor has been issued three additional patents, Patent No. 5,642,734, Patent No. 6,128,518 and Patent No. 6,766,191, each of which claims priority from October 4, 1990, the date of the first patent's filing, and each of which has an expiration date of October 4, 2010. Pursuant to a Development, Licensing and Manufacturing Agreement dated May 10, 2001 (the "2001 Agreement"), Chi Lxx xxx InMedica pursued additional development on the non-invasive hematocrit technology. The methods and procedures to measure hematocrit non-invasively, including without limitation, the patents and technologies incorporated in the patents and patent applications described above and the development work pursued by Chi Lxx xxx/or InMedica, are collectively referred to herein as the "Hematocrit Technology." InMedica is a publicly traded corporation. Chi Xxx xx a major shareholder of InMedica, owning one-third of the issued and outstanding shares of InMedica's common stock. MicroCor is a privately held corporation with 5,000,000 shares of common stock (the "MicroCor Stock") authorized under its Articles of Incorporation and no other class or series of stock authorized. InMedica and Chi Xxx xxx all of the issued and outstanding shares of the MicroCor Stock (147,101 shares), with InMedica owning 117,681 shares (80%) and Chi Lxx xxxxng 29,420 shares (20%). In order to facilitate further development of the Hematocrit Technology described in this Agreement, InMedica and Chi Lxx xxxxose to transfer, assign, or license their respective interests in the Hematocrit Technology to MicroCor. Wescor employs or has access to researchers and engineers to develop medical devices, equipment and products based on the Hematocrit Technology (the "Products"), and to conduct clinical trials of such products with the results thereof to be submitted to the U.S. Food and Drug Administration (the "FDA") to obtain clearance for marketing in the United States. It has the financial and managerial assets and experience to be capable of managing the process of developing and manufacturing the Products. The parties desire to enter into this Agreement with the intent of accomplishing the following pu...
Patent and Trademark Office. The Guarantor and each of its subsidiaries maintains a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since the end of the Guarantor’s most recent audited fiscal year, there has been (1) no material weakness in the Guarantor’s internal control over financial reporting (whether or not remediated) and (2) no change in the Guarantor’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Guarantor’s internal control over financial reporting.
Patent and Trademark Office. The United States Department of Commerce Patent and Trademark Office, Xxxxxxxxxx, XX 00000 and the Canadian Intellectual Property Office, Ottawa, Canada..
Patent and Trademark Office. The security interest granted hereby has been granted to the Collateral Agent in connection with the Security Agreement and is expressly subject to the terms and conditions thereof and does not create any additional rights or obligations for any party hereto. The Security Agreement (and all rights and remedies of the Collateral Agent thereunder) shall remain in full force and effect in accordance with its terms.
Patent and Trademark Office. The appointment of Bank as Grantor’s attorney in fact, and each and every one of Bank’s rights and powers, being coupled with an interest, is irrevocable until all of the Secured Obligations have been fully repaid and performed and Bank’s obligation to provide advances hereunder is terminated. Grantor hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue of this IP Security Agreement. Notwithstanding the foregoing, Bank agrees not to exercise its rights under the foregoing powers (other than as respects clauses (x) and (y) above) unless an Event of Default has occurred and is continuing.
Patent and Trademark Office. The Company agrees that a breach of this Section 4(t) shall not require that any notice of such by the holders of the Notes pursuant to Section 4(a)(xi) of the Notes or that any cure period be provided pursuant to such Section 4(a)(xi) of the Notes.
Patent and Trademark Office. The Escrow Agent shall hold and maintain the Reassignments and Clean Assignments in escrow hereunder until the first to occur of the following:
Patent and Trademark Office. In May 2000, we created European operating entities to support our international operations and opened our first data center outside of the United States. Located in London, our European SmartCenter(SM) gives Digex customers in Europe the superior level of technology, security, and support services in Europe they have come to rely on in the United States. The data center is a leased facility which became operational in July 2000. In January 2001, we received a $3.0 million loan from the State of Maryland Department of Business and Economic Development under the Sunny Day Fund initiative which may convert into a grant if certain conditions are met at specific maturity dates. Also, in January 2001, we were recently ranked by Gartner Research, a leading industry research firm, as one of only two leaders on their North American Web Hosting Magic Quadrant, and placed as the most visionary company in the ranking.
Patent and Trademark Office. The Executive hereby covenants that he shall execute all documents, and take all other actions after the date hereof as may be reasonably requested by the Company or which the Company believes are required to effectuate any such assignment of the Patents to the Company.
Patent and Trademark Office. P&G agrees to provide written notice to Paragon of the lapse of any such patent, and if applicable, the date that the patent has been maintained as a result of the acceptance by the U.S. Patent and Trademark Office of a delayed payment of the maintenance fee.
